Objective To investigate efficacy of elagolix plus add-back therapy (1 mg estradiol and 0.5
mg norethindrone acetate once daily) on patient-reported nonbleeding symptoms and …

Background Uterine fibroids are one of the most common neoplasms found among women
globally, with a prevalence of approximately 11 million women in the United States alone …

Objective Elagolix is an oral, non-peptide, gonadotropin-releasing hormone antagonist.
Elagolix was evaluated in premenopausal women with heavy menstrual bleeding (HMB;> …

Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …

Objective To evaluate the impact of elagolix, an oral gonadotropin-releasing hormone
antagonist, on the health-related quality of life (HRQL) in women with heavy menstrual …

Objective To evaluate the long-term safety of oral gonadotropin-releasing hormone receptor
elagolix (ELA) with hormonal add-back therapy (AB) in women with heavy menstrual …

Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Objective Evaluate safety and efficacy of elagolix (an oral GnRH antagonist) alone and
combined with low-dose estrogen+ progestin add-back therapy regimens in premenopausal …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

Objective: To evaluate the 6-month efficacy and safety of elagolix, an oral, non-peptide,
gonadotropin-releasing hormone antagonist, with/without add-back therapy, as compared to …